Imvax Co-Founder, Chief Scientific Officer
Professor, Departments of Cancer Biology and Neurological Surgery, Sidney Kimmel Cancer
As Chief Scientific Officer at Imvax, Inc., Dr. D. Craig Hooper is responsible for the company’s scientific, technological, and research operations. Dr. Hooper obtained his Doctorate in Immunology from McGill University, Montreal, Canada in 1983, beginning a long interest in the regulatory mechanisms that control immune responses to self, viral, and tumor antigens. Following post-doctoral studies and a faculty position at the University of Bristol in the UK, Dr. Hooper moved to the US, first to the University of Pennsylvania and then to Thomas Jefferson University both in Philadelphia, PA.
At Thomas Jefferson University, Dr. Hooper expanded his interests into neuroimmunity with ground-breaking studies in CNS inflammation and therapeutic immunity leading to a variety of therapeutic modalities, intellectual property and clinical trials in multiple sclerosis, Parkinson’s disease, and rabies virus infection. This, and his later work in cancer immunology, is detailed in close to 150 full-length publications and led to Dr. Hooper’s election as a Fellow of the National Academy of Inventors.
A 2001 meeting with Dr. David Andrews to discuss immunity in the context of brain cancer began a partnership responsible for development of the transformational approach to cancer immunotherapy which is the foundation of Imvax, Inc.